Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES FILING AMENDED AND RESTATED OFFERING DOCUMENT FOR NON-BROKERED PRIVATE PLACEMENT PURSUANT TO LISTED ISSUER FINANCING EXEMPTION

Ventripoint Diagnostics Ltd. has filed an amended and restated offering document in connection with its non-brokered private placement financing of up to $500,000 of units of the corporation at price of 19.5 cents per unit. The offering is being made to purchasers' resident in Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 (Prospectus Exempt Distributions). The securities offered under the listed issuer financing exemption will not be subject to a hold period in accordance with applicable Canadian securities laws. The amended and restated offering document includes changes to the anticipated use of funds from the offering, revised sales projections and other minor changes.

There is an offering document related to the offering that can be accessed under the company's profile and on the company's website. Prospective investors should read this offering document before making an investment decision.

Each unit will consist of one common share of the corporation and one share purchase warrant of the corporation. Each warrant will entitle the holder to purchase one share at a price of 30 cents per warrant share at any time on or before the date which is six months after issuance, subject to adjustment in certain events.

The corporation may pay cash finder's fee of up to 4 per cent of the gross proceeds of the offering. Finders may also receive common share purchase warrants equal to up to 4 per cent of the aggregate subscription amount in relation to subscribers introduced by the finder, each finder's warrant will be exercisable into one common share at an exercise price of 19.5 cents per common share for a period of six months.

The corporation will use the proceeds of the offering to fund operational costs related sales and marketing, additional key staff and general working capital purposes.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

We seek Safe Harbor.